Skip To Main Content
Jingtong Xu on Muck Rack

Jingtong Xu

As seen in: Wiley Online Library, BMJ Oncology, The BMJ, ACS Publications, BMC Cancer

Get in touch with Jingtong

Contact Jingtong, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

Clinicopathological and molecular correlates of clinical benefit from disitamab vedotin (RC48), a HER-2-targeting antibody-drug conjugate, in metastatic urothelial carcinoma: a multi-center, real-world study | BMC Cancer | Full Text

|
By Zhaopei Liu, Kaifeng Jin, Ziyue Xu, Han Zeng, Xiaohe Su, Jingtong Xu, Yawei Ding, Hailong Liu, yu zhu, Le Xu, Jiejie Xu, Zewei Wang, Yuan S. Chang
| BMC Cancer Verified
From April 2021 to March 2024, we searched for and included the UC patients who were prescribed for DV treatment, with primary sites including the renal pelvis, ureter, and bladder. This study involves three independent institutions: Fudan University Shanghai Cancer Center (FUSCC), Zhongshan Hospital Fudan University (ZSHS), and Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine (XHHS).
Open in Who Shared Issue with article?

Enantioselective Synthesis of Spirocyclic Nitrogen-Containing Heterocycles Catalyzed by an Iridium-Containing Cytochrome

|
By Jingtong Xu, Brandon Bloomer, John N. Brunn, Andrew P. Quest
| dx.doi.org
Open in Who Shared Issue with article?

Novel Aptamer-Drug Conjugate for Targeted Therapy in Triple-Negative Breast Cancer

|
By Feng Xu, Jingtong Xu, Feng Han, Ke Wang
| ACS Publications
Open in Who Shared Issue with article?
See all 12 articles